Legacy AI grade · Sources dated 2026-06-09. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow
Iodine for Fibrocystic Breast
Across 3 PubMed studies, the evidence for Iodine in Fibrocystic Breast grades Tier C — weak evidence. Effective, but with safety or population caveats.
Why this grade7-layer evidence engine
Iodine for fibrocystic breast disease has a small, dated evidence base. PMID 29237134 tests a multi-ingredient liquid nutritional formula, not iodine monotherapy, and should not count as an iodine-only RCT.
evidence_level_desc claimed '3 smaller RCTs' without excluding the combination product. True iodine-monotherapy trials are fewer and methodologically limited.
Tier C reflects weak evidence. Iodine supplementation carries thyroid interaction risks and should not be self-prescribed for breast symptoms.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.508
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標,未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status